Hexyl aminolevulinate, 5-aminolevulinic acid nanoemulsion, and methyl aminolevulinate in photodynamic therapy of non-aggressive basal cell carcinomas: A non-sponsored, randomized, prospective and double-blinded trial

Show full item record



Permalink

http://hdl.handle.net/10138/325221

Citation

Salmivuori , M , Grönroos , M , Tani , T , Pölönen , I , Räsänen , J , Annala , L , Snellman , E & Neittaanmäki , N 2020 , ' Hexyl aminolevulinate, 5-aminolevulinic acid nanoemulsion, and methyl aminolevulinate in photodynamic therapy of non-aggressive basal cell carcinomas: A non-sponsored, randomized, prospective and double-blinded trial ' , Journal of the European Academy of Dermatology and Venereology , vol. 34 , no. 12 , pp. 2781-2788 . https://doi.org/10.1111/jdv.16357

Title: Hexyl aminolevulinate, 5-aminolevulinic acid nanoemulsion, and methyl aminolevulinate in photodynamic therapy of non-aggressive basal cell carcinomas: A non-sponsored, randomized, prospective and double-blinded trial
Author: Salmivuori, M.; Grönroos, M.; Tani, T.; Pölönen, I.; Räsänen, J.; Annala, L.; Snellman, E.; Neittaanmäki, N.
Other contributor: University of Helsinki, HYKS erva
University of Helsinki, HYKS erva
University of Helsinki, Päijät-Häme Welfare Consortium




Date: 2020-12
Language: eng
Number of pages: 8
Belongs to series: Journal of the European Academy of Dermatology and Venereology
ISSN: 0926-9959
DOI: https://doi.org/10.1111/jdv.16357
URI: http://hdl.handle.net/10138/325221
Abstract: Abstract Background In the photodynamic therapy (PDT) of non-aggressive basal cell carcinomas (BCCs), 5-aminolevulinic acid nanoemulsion (BF-200ALA) has shown non-inferior efficacy when compared with methyl aminolevulinate (MAL), a widely used photosensitizer. Hexyl aminolevulinate (HAL) is an interesting alternative photosensitizer. To our knowledge, this is the first study using HAL-PDT in the treatment of BCCs. Objectives To compare the histological clearance, tolerability (pain and post-treatment reaction), and cosmetic outcome of MAL, BF-200 ALA, and low-concentration HAL in the PDT of non-aggressive BCCs. Methods Ninety-eight histologically verified non-aggressive BCCs met the inclusion criteria, and 54 patients with 95 lesions completed the study. The lesions were randomized to receive LED-PDT in two repeated treatments with MAL, BF-200 ALA, or HAL. Efficacy was assessed both clinically and confirmed histologically at three months by blinded observers. Furthermore, cosmetic outcome, pain, post-treatment reactions fluorescence, and photobleaching were evaluated. Results According to intention-to-treat analyses, the histologically confirmed lesion clearance was 93.8% (95% confidence interval [CI] = 79.9?98.3) for MAL, 90.9% (95% CI = 76.4?96.9) for BF-200 ALA, and 87.9% (95% CI = 72.7?95.2) for HAL, with no differences between the arms (p=0.84). There were no differences between the arms as regards pain, post-treatment reactions, or cosmetic outcome. Conclusions PDT with low-concentration HAL and BF-200 ALA have a similar efficacy, tolerability, and cosmetic outcome compared to MAL. HAL is an interesting new option in dermatological PDT, since good efficacy is achieved with a low concentration.
Subject: 3122 Cancers
non-aggressive basal cell carcinoma
photodynamic therapy
methyl aminolevulinate
5-aminolevulinic acid nanoemulsion
hexyl aminolevulinate
MANAGEMENT
PROTOPORPHYRIN IX FORMATION
TOPICAL IMIQUIMOD
FLUOROURACIL
SINGLE-BLIND
ANESTHESIA
PAIN
EUROPEAN GUIDELINES
SKIN
BOWENS-DISEASE
Rights:


Files in this item

Total number of downloads: Loading...

Files Size Format View
jdv.16357.pdf 10.81Mb PDF View/Open
jdv.16357.pdf 728.6Kb PDF View/Open

This item appears in the following Collection(s)

Show full item record